Azusa, California 91702


Purpose:

Sickle cell disease is a life-threatening genetic disorder that can be effectively treated following early diagnosis via newborn screening. However, sickle cell disease is most prevalent in low-resource regions of the world, where newborn screening is rare due to the cost and logistical burden of laboratory-based methods. In many such regions, >80% of affected children die, undiagnosed, before the age of five years. A convenient and inexpensive point-of-care test for sickle cell disease is thus crucially needed. In this study we will conduct a blinded, multicenter, prospective diagnostic accuracy study of HemoTypeSC(TM), an inexpensive 15-minute point-of-care immunoassay for detecting sickle cell disease, hemoglobin C disease, and trait phenotypes in newborns, children, and adults.


Criteria:

Inclusion Criteria: - Agrees to be enrolled (or has parent/guardian approval to be enrolled) Exclusion Criteria: - Previous sickle cell screening


NCT ID:

NCT03619798


Primary Contact:

Erik Serrao, PhD
Phone: 3103872866
Email: eserrao@silverlakeresearch.com


Backup Contact:

N/A


Location Contact:

Azusa, California 91702
United States

Erik Serrao
Phone: 310-387-2866
Email: eserrao@silverlakeresearch.com

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.